PRODUCT INFORMATION



Isoguvacine (hydrochloride)

Item No. 33143

CAS Registry No.:	68547-97-7	
Formal Name:	1,2,3,6-tetrahydro-4-pyridinecarboxylic acid,	_
	monohydrochloride	0
MF:	$C_6H_9NO_2 \bullet HCI$	
FW:	163.6	└ \ `OH
Purity:	≥95%	N. • HCI
Supplied as:	A crystalline solid	Н
Storage:	-20°C	
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Isoguvacine (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the isoguvacine (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Isoguvacine (hydrochloride) is soluble in the organic solvent DMSO at a concentration of approximately 1 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of isoguvacine (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of isoguvacine (hydrochloride) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Isoguvacine is a GABA_{Δ} receptor agonist.¹ It binds to rat synaptic cortical membranes (K_i = 55 nM) and activates $\alpha_1\beta_2\gamma_{2S}$, $\alpha_2\beta_2\gamma_{2S}$, $\alpha_3\beta_2\gamma_{2S}$, $\alpha_5\beta_2\gamma_{2S}$, and ρ_1 subunit-contanining GABA_A receptors in a FLIPR assay (EC₅₀s = 13, 4.5, 5.6, 0.78, and 3.1 µM, respectively).¹ It inhibits CA1 population spikes in rat hippocampal slices (EC₅₀ = 13 μ M) and high potassium/low magnesium-induced seizures in rat pups.^{2,3} Chronic administration of isoguvacine (2 mg/kg) improves tactile over-reactivity, anxiety-like behaviors, and social impairments in mouse models of autism spectrum disorder (ASD).⁴

References

- 1. Petersen, J.G., Sørensen, T., Damgaard, M., et al. Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABA receptor agonists. Eur. J. Med. Chem. 84, 404-416 (2014).
- 2. Kemp, J.A., Marshall, G.R., and Woodruff, G.N. Quantitative evaluation of the potencies of GABAreceptor agonists and antagonists using the rat hippocampal slice preparation. Br. J. Pharmacol. 87(4), 677-684 (1986).
- 3. Isaev, D., Isaeva, E., Khazipov, R., et al. Anticonvulsant action of GABA in the high potassium-low magnesium model of ictogenesis in the neonatal rat hippocampus in vivo and in vitro. J. Neurophysiol. 94(4), 2987-2992 (2005).
- 4. Orefice, L.L., Mosko, J.R., Morency, D.T., et al. Targeting peripheral somatosensory neurons to improve tactile-related phenotypes in ASD models. Cell 178(4), 867-886 (2019).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM